Announcement on Outline of the Q3 2025 Performance Briefing
Filed with SSE · · 4 pages · Chinese
Summary by 6ix AI
The company addressed various investor inquiries regarding its operational results and financial status during the briefing. Key topics included the expansion of new product production lines, the impact of rising costs on profits, and the company's future growth strategies. The company confirmed its commitment to maintaining stable dividends and discussed its digital transformation efforts in the pharmacy sector.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhuzhou Qianjin Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhuzhou Qianjin Pharmaceutical
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
- Announcement on Convening the Q3 2025 Performance Briefing
- Announcement on Main Operating Data for Q3 2025
- Announcement on the Implementation of Issuance of Shares and Payment in Cash for Asset Purchase and Related Party Transactions and Changes in Capital Shares
- Announcement on Amendment to Report on Purchasing Assets through Issuance of Shares and Cash Payment and Related Party Transaction
Later from Zhuzhou Qianjin Pharmaceutical
- Announcement on Profit and Loss during Transition Period of Underlying Assets Related to the Company's Issuance of Shares and Payment of Cash to Purchase Assets and Related Party Transactions
- Announcement on Changing the Independent Financial Advisor for Continuous Supervision
- Announcement on Resolutions of the 15th Meeting of the 11th Board of Directors
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
- Announcement on the Approval of Buoxue Yimu Pill as a National Protected Traditional Chinese Medicine Variety
Follow Zhuzhou Qianjin Pharmaceutical into a list and get an email when it puts out news.
Follow Zhuzhou Qianjin Pharmaceutical